BioPharma Resources

Drug Trial Radar · NCT06333808

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 577 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

577

Actual

Start

Mar 25, 2024

Primary completion

Oct 27, 2025

Study completion Dec 2029

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH) who are successfully treated with B/F/TAF (virologically suppressed). The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) FDC tablets versus continuing on B/F/TAF (50/200/25 mg) FDC tablets in virologically suppressed PWH.

Conditions

  • HIV-1-infection

Interventions

  • Bictegravir/Lenacapavir (BIC/LEN) FDCDrug

    Tablets administered orally without regard to food

  • LenacapavirDrug

    Tablets administered orally without regard to food

  • B/F/TAFDrug

    Tablets administered orally without regard to food

  • Placebo to match B/F/TAFDrug

    Tablets administered orally without regard to food

  • Placebo to match BIC/LEN FDCDrug

    Tablets administered orally without regard to food

  • Placebo to match LenacapavirDrug

    Tablets administered orally without regard to food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot AlgorithmTime frame: Week 48

Locations

104 sites in 14 countries. Site status is shown where the registry gives one.

  • Pueblo Family Physicians

    Phoenix, Arizona

  • Be Well Medical Center

    Berkeley, California

  • Pacific Oaks Medical Group

    Beverly Hills, California

  • Ruane Clinical Research Group Inc.

    Los Angeles, California

  • Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care

    Oakland, California

  • BIOS Clinical Research

    Palm Springs, California

  • UCSD Anti Viral Research Centre (AVRC)

    San Diego, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Mills Clinical Research

    West Hollywood, California

  • Public Health Institute at Denver Health

    Denver, Colorado

  • Yale University School of Medicine (study visits)

    New Haven, Connecticut

  • Midland Florida Infectious Diseases Specialists, PL - Orange City

    DeLand, Florida

  • Therafirst Medical Center

    Fort Lauderdale, Florida

  • CAN Community Health

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • AIDS Healthcare Foundation - The Kinder Medical Group

    Miami, Florida

  • Schiff Center for liver Diseases/University of Miami

    Miami, Florida

  • Floridian Clinical Research

    Miami Lakes, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Bliss Healthcare

    Orlando, Florida

  • AHF Pensacola

    Pensacola, Florida

  • CAN community Health

    Sarasota, Florida

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida

  • Infectious Disease Specialists of Atlanta

    Decatur, Georgia

  • Mercer University, Department of Internal Medicine

    Macon, Georgia

  • Claudia T Martorell MD LLC dba The Research Institute

    Springfield, Massachusetts

  • Henry Ford Health

    Detroit, Michigan

  • KC Care health Center

    Kansas City, Missouri

  • Southampton Community Healthcare, Inc.

    St Louis, Missouri

  • ID Care, LLC

    Hillsborough, New Jersey

  • Saint Michael's Medical Center

    Newark, New Jersey

  • New Jersey Medical School - Clinical Research Center

    Newark, New Jersey

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • AXCES Research Group, LLC

    Santa Fe, New Mexico

  • New York-Presbyterian Queens

    Flushing, New York

  • Montefiore Medical Center

    The Bronx, New York

  • The Brody School of Medicine at East Carolina University , ECU Adult Specialty Care

    Greenville, North Carolina

  • Rosedale Health and Wellness

    Huntersville, North Carolina

  • Philadelphia FIGHT Community Health Centers

    Philadelphia, Pennsylvania

  • Medical University of South Carolina (MUSC) Research Nexus

    Charleston, South Carolina

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.